Samer Choucair: U.S. Debt Is Repricing Risk and Redirecting Capital Toward Healthcare and Robotics
Investment leader Samer Choucair said the U.S. national debt surpassing the $40 trillion threshold represents a turning point in the pricing of global risk. He argued that the figure should not be interpreted in isolation, but rather as the result of a long-term trajectory of persistent deficits and rising debt-servicing costs that is forcing investors to reassess the cost of capital and expected asset returns in the years ahead.
Samer Choucair said sustained fiscal deficits and higher interest payments are making long-duration yields increasingly important in investment decisions. Higher financing costs affect equity valuations, corporate borrowing, mergers and acquisitions, and infrastructure projects, while also increasing the sensitivity of emerging markets to changes in U.S. Treasury yields.
“Rising debt does not eliminate the dollar’s status or the depth of the U.S. Treasury market, but it increases the cost of ignoring fiscal discipline in capital-allocation models,” Choucair said. “Investors are not dealing only with default risk. They also face the possibility of a persistent term premium, structurally higher financing costs, and greater competition between government issuance and private-sector capital needs.”
Choucair said the current environment is encouraging institutional investors to separate liquidity and hedging assets from long-term growth assets, while placing greater emphasis on companies and sectors capable of generating genuine productivity improvements rather than growth driven primarily by cheap money.
Healthcare as a Growth Engine
Samer Choucair said recent developments in biotechnology provide a clear example of innovation-led growth.
Moderna and Merck have reported positive Phase 3 results from the INTerpath-001 study evaluating a personalized mRNA-based therapy in combination with Keytruda for patients with high-risk melanoma following surgical resection. The study enrolled 1,137 patients, and Choucair said the investment significance extends beyond the value of the therapy itself.
The broader opportunity, he argued, reaches across an entire ecosystem that includes molecular diagnostics, genomic sequencing, personalized-treatment manufacturing, specialized logistics, and clinical-trial infrastructure.
“When a therapeutic platform moves from scientific promise to positive Phase 3 evidence, capital begins to reprice the entire platform,” Choucair said. “But a professional investor does not stop at the clinical result. The next questions are manufacturing, pricing, reimbursement, and whether the treatment can expand into additional indications.”
Choucair said successful commercialization of personalized medicine could create new investment opportunities across biotechnology, healthcare services, diagnostics, and specialized manufacturing.
However, he cautioned that scientific success alone is not sufficient. The sector must also demonstrate that personalized therapies can achieve economic viability at scale, particularly given the complexity of manufacturing and delivering treatments tailored to individual patients.
Robotics and the Productivity Race
Samer Choucair said the rapid expansion of robotics, particularly in China, reflects a transition from technology demonstrations toward practical deployment across production lines, logistics, and manufacturing.
He argued that institutional investors should not measure the robotics sector by the number of new products announced or the amount of media attention it receives. Instead, the most important question is whether automation can reduce operating costs, increase productivity, and generate sustainable cash flows.
“Robotics will ultimately be valued by how much it lowers operating costs, not by how impressive it looks at exhibitions,” Choucair said. “Smart capital will look for real contracts, utilization rates, industrial purchase orders, and measurable productivity gains rather than simply buying into the artificial-intelligence narrative.”
For investors, this distinction is becoming increasingly important as robotics attracts capital from companies and funds seeking exposure to artificial intelligence and automation.
Choucair said businesses capable of proving a quantifiable economic return from robotic systems could command stronger long-term valuations than companies dependent primarily on technological novelty.
An Investment Opportunity for the Gulf
Choucair said the combination of higher global financing costs and rapid technological innovation presents Gulf economies with an opportunity to redesign portfolios around credit quality, productivity-supported growth, and localized value chains.
Higher global borrowing costs make debt-duration management, diversified funding sources, and greater discipline in capital expenditure more important for large-scale projects.
At the same time, the relatively strong financial positions of several Gulf economies can provide them with the capacity to make long-duration investments in biotechnology, advanced manufacturing, automation, and related infrastructure.
“The Gulf investor does not need to choose between hedging against U.S. debt risk and investing in innovation,” Choucair said. “What is required is a separation between the liquidity horizon and the growth horizon: maintaining high-quality, liquid assets while making selective long-term allocations to sectors with genuine scientific or industrial barriers to entry.”
According to Samer Choucair, that approach could allow Gulf institutions to use financial strength not simply to purchase international assets, but to acquire strategic positions within emerging global value chains.
Investments in biotechnology platforms, medical manufacturing, industrial automation, robotics, data infrastructure, and advanced production systems could provide exposure to structural trends that are less dependent on falling interest rates than many conventional growth strategies.
Reengineering Institutional Portfolios
Samer Choucair said 2026 is forcing investors to reconsider the relationship between debt, liquidity, and growth.
The expansion of U.S. public debt makes duration and credit-risk management increasingly important, while biotechnology and robotics provide potential sources of growth that do not rely exclusively on abundant and inexpensive liquidity.
“The new investment equation is based on three prices that must be monitored simultaneously: the price of money, the price of innovation, and the price of productivity,” Choucair said. “Anyone who ignores the higher cost of capital risks overvaluing growth. Anyone who ignores genuine innovation risks missing long-term opportunities. And anyone who follows narratives without measuring cash flow exposes the portfolio to valuation risk.”
He added that the objective is neither to become structurally pessimistic about U.S. debt nor unconditionally optimistic about technology.
Instead, institutional investors should redesign expected returns around asset quality, sustainable cash-flow generation, competitive advantages, and the ability of companies to create measurable economic value.
“The goal is not pessimism about U.S. debt or unconditional optimism about technology,” Samer Choucair said. “It is to reengineer returns around the quality of assets and their ability to generate real value. In the Gulf, investment institutions have an opportunity to transform strong financial positions into strategic ownership across the value chains of the future, from biotechnology to advanced manufacturing and robotics.”